ZENITHDRUGZenith Drugs Ltd.

₹63.35-2.16%

Market Cap

₹111.04 Cr

Stock P/E

11.58

ROCE

25.15%

ROE

24.12%

Book Value

₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Growth Outperformer

Zenith Drugs Ltd. exhibits strong profitability metrics but lacks growth and valuation appeal compared to peers. It holds promising efficiency ratios but needs to address its revenue stagnation to compete effectively. Among peers, firms like Cipla Ltd. and Mankind Pharma Ltd. show strong growth and profitability, while Sun Pharmaceutical Industries Ltd. appears overvalued despite decent operational performance.

Key Points

• Zenith Drugs Ltd. has strong ROE at 24.12% but no revenue growth.
• Cipla Ltd. and Mankind Pharma Ltd. are standout growth performers with strong YoY revenue increases.
• Sun Pharmaceutical Industries Ltd. is significantly overvalued with a PE of 87.59.
• Divi's Laboratories Ltd. shows weaknesses in revenue growth despite a high EPS and ROCE.
• Companies like Torrent Pharmaceuticals and Dr. Reddy's show solid profitability but face valuation concerns.

Top Performers

Cipla Ltd.

Strong revenue growth (13.28% YoY), solid profitability metrics, and reasonable valuation.

Mankind Pharma Ltd.

Exceptional revenue growth (18.12% YoY) and strong profitability ratios.

Dr. Reddy's Laboratories Ltd.

High profitability with a ROE of 21.76% and attractive valuation metrics.

Explore

Watchlists

Command Palette